Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15997242 | 0.85 | LMNA (0.41) | SMN1; SMN2ALDH1A1TRPA1CYP1A2LMNA | |
| SCHEMBL17655562 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TRPA1CYP1A2LMNA | |
| SCHEMBL15997195 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1TRPA1CYP1A2LMNA | |
| SCHEMBL22261569 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1TRPA1 | |
| SCHEMBL9319516 | 0.74 | ALDH1A1 (0.50) | SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1TRPA1 | |
| SCHEMBL15987580 | 0.74 | CA12 (0.42) | SMN1; SMN2ALDH1A1TRPA1CYP1A2LMNA | |
| Hydrochloric Acid SCHEMBL11582693 | 0.73 | ALDH1A1 (0.48) | SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1TRPA1 | |
| SCHEMBL15997231 | 0.71 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1TRPA1CYP1A2LMNA | |
| SCHEMBL10851453 | 0.71 | APOBEC3A (0.56) | SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1TRPA1 | |
| SCHEMBL22269119 | 0.70 | ALDH1A1 (0.42) | SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2772490-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013062065-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | アステラス製薬株式会社 (JP) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | SLC34A2, SLC10A2, ALPI | SMN1; SMN2 4486/4885APOBEC3A 4581/4885APOBEC3G 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.